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Summary
Plants can provide a cost-effective and scalable technology for production of therapeutic
monoclonal antibodies, with the potential for precise engineering of glycosylation. Glycan
structures in the antibody Fc region influence binding properties to Fc receptors, which opens
opportunities for modulation of antibody effector functions. To test the impact of glycosylation
in detail, on binding to human Fc receptors, different glycovariants of VRC01, a broadly
neutralizing HIV monoclonal antibody, were generated in Nicotiana benthamiana and
characterized. These include glycovariants lacking plant characteristic a1,3-fucose and b1,2-
xylose residues and glycans extended with terminal b1,4-galactose. Surface plasmon resonance-
based assays were established for kinetic/affinity evaluation of antibody–FccR interactions, and
revealed that antibodies with typical plant glycosylation have a limited capacity to engage FccRI,
FccRIIa, FccRIIb and FccRIIIa; however, the binding characteristics can be restored and even
improved with targeted glycoengineering. All plant-made glycovariants had a slightly reduced
affinity to the neonatal Fc receptor (FcRn) compared with HEK cell-derived antibody. However,
this was independent of plant glycosylation, but related to the oxidation status of two
methionine residues in the Fc region. This points towards a need for process optimization to
control oxidation levels and improve the quality of plant-produced antibodies.
Introduction
Antibody-based therapeutics comprise a major segment of the
fast-growing biopharmaceutical market. There are currently
more than 50 monoclonal antibodies approved for clinical use,
and hundreds are in preclinical and clinical development (Ecker
et al., 2015). Most of these are IgG antibodies that target
cancer and autoimmune disorders, although there is growing
interest in monoclonal antibodies to tackle infectious diseases
(Irani et al., 2015). Whilst binding to cognate antigen is the
hallmark of antibody function, engagement of cell-surface Fc
receptors can activate immune cells to remove or neutralize
antibody-coated targets via processes known collectively as
antibody effector functions (Desjarlais and Lazar, 2011). There
are six classical Fc receptors recognizing IgG: high-affinity FccRI
(CD64) and low-affinity FccRIIa, FccRIIb, FccRIIc (CD32a-c),
FccRIIIa and FccRIIIb (CD16a and b); and their cooperation on
immune cells surface allows for a tailored cellular response
against the target. Interaction of the antibody Fc region with
FccRs is influenced by glycans attached to a highly conserved
N-glycosylation site within the Fc fragment, and their
composition can influence binding affinity and receptor-medi-
ated activity (Jefferis, 2009b).
An important feature of IgG antibodies is their long serum half-
life, which extends their therapeutic and protective effect (Ward
et al., 2015). Rapid clearance of IgG from the circulation is
prevented by interaction with neonatal Fc receptor (FcRn), which
protects IgG antibodies from endosomal degradation (Junghans
and Anderson, 1996). FcRn is a membrane heterodimer protein,
which belongs to the MHC class I molecular family (Burmeister
et al., 1994). Recent studies have demonstrated that efficacy of
antibody therapy correlates with serum half-life and that
engineering antibodies to prolong their lifespan in the blood
extends their therapeutic effect (Ko et al., 2014; Zalevsky et al.,
2010).
The importance of Fc receptor interactions was recently
highlighted for broadly neutralizing antibodies (bNAbs) in
protection against HIV infection (Gautam et al., 2016; Ward
et al., 2015). Various studies suggest that bNAbs can control
persistent viral reservoirs, raising the possibility of their use for
treating infected individuals (Caskey et al., 2015; Chun et al.,
2014). Protective and therapeutic effects of antibodies are
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largely dependent on the antibody Fc region, and were
dramatically decreased when FcR-binding activities were engi-
neered out of the antibodies (Bournazos et al., 2014). The
role of FccRs in antibody-mediated protection against HIV
infection was further emphasized in the RV144 vaccine trial,
where an estimated 30% of vaccinated individuals were
protected from acquiring HIV. Detailed analysis revealed that
the protective effect correlated with induction of IgG3
responses and high ADCC activity of the elicited antibodies
(Chung et al., 2014).
One of the first broadly neutralizing HIV antibodies discovered
using next-generation methods, VRC01 (Wu et al., 2010), has
rapidly become an important clinical candidate for HIV prevention
and treatment (Ledgerwood et al., 2015). A single injection of
VRC01 antibody provided 8-week protection against HIV infec-
tion in macaques, which was extended to 14.5 weeks by
improving its binding to FcRn (Gautam et al., 2016). Moreover,
an engineered VRC01 demonstrated increased FcRn-mediated
delivery to gut mucosal tissue resulting in enhanced mucosal
localization and improved protection against SHIV challenge (Ko
et al., 2014). In humans, VRC01 has been the subject of
numerous completed and current clinical trials (Bar et al., 2016;
Crowell et al., 2019; Riddler et al., 2018), which all demonstrate
that the antibody is safe and well-tolerated. Whilst protective
efficacy has not been prominent, it is widely agreed that
monoclonal antibody monotherapy is insufficient and that com-
bination therapy with at least two mAbs is a minimum require-
ment (Mendoza et al., 2018).
Plants are becoming established as a ‘low-tech’, cost-effective
and scalable production system for biopharmaceuticals including
monoclonal antibodies (mAbs) (Paul et al., 2013). Molecular
pharming is particularly attractive in the field of HIV antibody
therapeutics as the major limitation of antibody-based anti-HIV
agents remains their high cost of manufacturing (Ma et al.,
2013). Recently, the first GMP manufacturing licence for plant
mAbs was awarded in Europe, which led to a first-in-man phase I
clinical trial (Ma et al., 2015). The only significant difference
between mAbs produced in plant and mammalian cells results
from different glycosylation pathways leading to production of
antibodies with different glycan composition. Plant glycoproteins
are characterized by core a1,3-fucose and b1,2-xylose resides,
and lack of galactose and sialic acid residues (Bosch et al., 2013),
which was shown to have a negative impact on ADCVI (antibody-
dependent cell-mediated virus inhibition) activity against HIV of
some (Forthal et al., 2010), but not all (Rosenberg et al., 2013),
plant-produced antibodies.
mAb VRC01 expressed in plants demonstrated similar antigen
binding and HIV neutralization activity to VRC01 produced in HEK
cells (Rosenberg et al., 2013; Teh et al., 2014). However, plant-
derived VRC01 was cleared rapidly from the bloodstream in
macaques (Rosenberg et al., 2013). The reason for the rapid
clearance observed for some plant-made antibodies is unknown,
and results are inconsistent (Khoudi et al., 1999; Lee et al., 2013;
Triguero et al., 2011). It has been suggested that distinct
glycosylation of recombinant antibodies expressed in nonhuman
systems might have an indirect effect on FcRn binding (Jefferis,
2009a), even though human glycosylation does not affect
binding of IgG to FcRn directly, because the receptor does not
come in close contact with the Fc glycans (Martin et al., 2001;
Nezlin and Ghetie, 2004).
In this study, the primary objective was to perform a compre-
hensive analysis of the impact of glycosylation on mAb VRC01
interactions with Fc receptors. Also, other post-translational
modifications, like methionine oxidation, were assessed in the
context of FcRn binding. A panel of engineered glycovariants of
VRC01 were generated in N. benthamiana, and Fc-gamma
receptor binding was characterized by kinetics and affinity
measurement as well as effector function. The plant-derived
antibodies were evaluated for interactions with FcRn.
Results
VRC01 antibody glycovariants produced in
N. benthamiana
cDNA sequences encoding antibody heavy and light chains were
cloned into a binary vector (Sainsbury et al., 2009) and transiently
expressed in N. benthamiana using agroinfiltration (Kapila et al.,
1997). Purified antibodies were subjected to glycan analysis by
liquid chromatography–electrospray ionization-mass spectrome-
try (LC-ESI-MS) to identify and quantify N-glycan populations in
the Fc region. Each glycovariant was produced in 2–3 batches,
and successful glycoengineering of extra batches was confirmed
by immunoblotting (data not shown). Mass spectra of tryptic
glycopeptides revealed that the main structure on VRC01
expressed transiently in WT N. benthamiana (VRC01WT) is a
typical plant glycan with b1,2-xylose and core a1,3-fucose
residues (GnGnXF3), accounting for 54.1% of the entire popu-
lation (Table 1, Figure S1). A high proportion of VRC01WT heavy
Table 1 Percentage composition of N-glycan populations on the heavy chains of different VRC01 glycovariants
VRC01 HEK VRC01 WT VRC01 ΔXF VRC01 Gal
GnGnF6 70.5% GnGnXF3 54.1% GnGn 74.6% unglyc. 29.4%
GnAF6 17.2% unglyc. 35.9% unglyc. 21.1% MA + Man4Gn 28.7%
unglyc. 3.1% MGnXF3 3.7% MGn 4.3% Man4A + Man5Gn 10.8%
MGnF6 2.7% MMXF3 2.5% Man5A 9.9%
GnAF6bi 2.4% Man8 1.2% MGn 9.3%
AAF6 1.9% Man9 1.0% AA 7.8%
Man5 1.2% Man7 0.7% GnGn 3.3%
UGnF6 0.9% Man5 0.7% MM 0.9%
Man6 0.4%
Structures and abbreviations of N-glycans which constitute <5% of the total population have been formatted in bold. Unglyc.–unglycosylated heavy chain.
Abbreviations according to the ProGlycAn nomenclature (http://www.proglycan.com/protein-glycosylation-analysis/nomenclature).
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chains (36%) appeared to be unglycosylated, and there were also
minor populations of incompletely processed glycans. VRC01
expressed in the DXT/FT plant line (VRC01DXF), where b1,2-
xylosylation and core a1,3-fucosylation had been silenced
(Strasser et al., 2008), demonstrated a homogenous glycosylation
pattern with a dominant structure GnGn (74.6%). No xylosylated
or fucosylated glycan structures were detected, and in this case,
21.2% of the heavy chains were unglycosylated. To further
modify the plant N-glycans by addition of terminal b1,4-galac-
tose, VRC01 was co-expressed with a human b1,4-galactosyl-
transferase targeted to the late Golgi compartment, in the DXT/FT
plant line (VRC01Gal). This resulted in heterogeneous glycosyla-
tion of the heavy chains, with several structures (approx. 50%)
carrying at least one galactose residue. As in VRC01ΔXF, no xylose
and fucose residues could be detected in the VRC01Gal heavy
chain. Almost 30% of VRC01Gal heavy chains were
unglycosylated.
The glycosylation profile of VRC01 antibody derived from HEK
cells was also analysed (VRC01HEK), revealing a heterogeneous
pattern with the most prevalent structure being GnGnF6 (70.5%).
Galactosylated structures, but not sialylated, were also present.
3.1% of the heavy chains were unglycosylated. Finally, a plant-
produced VRC01 variant lacking Fc N-glycans was created by site-
directed mutagenesis (VRC01aglyco). Disruption of the N-glycosy-
lation site by N297S mutation was verified through DNA
sequencing, and the absence of N-glycans on the heavy and
light chains was further indicated at the protein level by SDS-
PAGE of antibodies analysed under reducing conditions (data not
shown).
Binding kinetics and affinity of VRC01 to FccRI and
FccRIIIa
Binding kinetics and affinities of mAb Fc interactions with FccRs
were performed using surface plasmon resonance. Each VRC01
glycovariant was individually captured onto a protein A-coated
sensor chip, and recombinant human FccRI ectodomains were
injected over the antibody surface at a range of concentrations.
Sensorgrams were analysed with a 1 : 1 binding model except for
VRC01WT where a modified version of the heterogeneous ligand
binding model was used to fit the biphasic binding behaviour of
the unglycosylated and glycosylated mix in VRC01WT (Figure 1a).
The model was created by incorporating kinetic parameters for
unglycosylated VRC01 to the heterogeneous binding model to
cover the unglycosylated portion of VRC01WT and thus to extract
kinetics for the glycosylated portion of VRC01WT.VRC01Gal was
also tested with both this heterogeneous binding model that
assumes an aglycosylated portion of VRC01 and the standard
1 : 1 binding model (Figure S2). The same kinetics for galacto-
sylated VRC01 were obtained regardless of the model choice—
the aglycosylated portion of VRC01Gal was recognized and
Figure 1 Interaction of VRC01 glycovariants with
recombinant human FccRI and FccRIIIa. (a) SPR
sensorgrams illustrate binding and dissociation of
antibody–receptor complexes. Data were analysed
with a 1 : 1 binding interaction model for FccRI
(except VRC01WT; see text for details) and a two-
state reaction interaction model for FccRIIIa.
Dashed line denotes maximum response upon
saturation. Theoretical saturation level is displayed
separately as a solid line if it differs or could not be
extrapolated from the data. Receptor
concentrations used: FccRI at 2–240 nM (15–
480 nM for VRC01aglyco), and FccRIIIa at 125–
4000 nM for fucosylated antibodies and 12–
800 nM for afucosylated ones. Data shown are
from one experiment representative of at least
two technical repeats. (b) Kinetic map for the
interaction of antibodies with FccRI based on
association rate (on-rate) and dissociation rate
(off-rate) constants. For VRC01WT, the kinetics
parameters of the glycosylated portion were used.
(c) Half-life of the antibody–FccRI complexes as
calculated from the dissociation rate constants.
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discarded by the 1 : 1 binding model as artefact. Accordingly, the
simplest model (usually 1 : 1 binding kinetics) was always chosen.
Chi-squared values were assessed for all kinetics analysis, and
data are only reported when deviation of the fit was <5% Rmax.
VRC01HEK had the highest affinity to FccRI with a dissociation
constant (KD) of 98 pM, and VRC01DXF and VRC01Gal had KDs
of 247 pM and 558 pM, respectively (Figure 3). VRC01WT formed
significantly less stable complexes with the receptor (KD = 3 nM),
and removing Fc glycosylation reduced affinity to FccRI by
another order of magnitude (71 nM, VRC01aglyco) and caused
immediate dissociation of the antibody–receptor complex (Fig-
ure 1a). Kinetic analysis revealed that changes in glycosylation
mainly affected the dissociation rate constant, without influenc-
ing the association rate constant significantly (Figure 1b). As a
consequence, glycosylation altered stability of antibody–FccRI
complexes, reducing their half-life from about 1 h to 5 min for
typical plant N-glycans, and to only seconds for unglycosylated
antibodies (Figure 1c).
To study binding to FccRIIIa, a polymorphic variant with high
affinity to IgG1, FccRIIIa-V158 (Ravetch and Perussia, 1989),
was selected. Previous studies demonstrated that the interac-
tion does not follow the 1 : 1 binding model despite 1 : 1
stoichiometry (Frostell, 2015), probably due to conformational
change that may occur during the binding event (Hayes et al.,
2014). Three-dimensional structures of the FccRIIIa–Fc complex
suggest that the receptor makes close contact with one arm of
the heavy chain first and then locks its position in between the
two chains (Ferrara et al., 2011). For these reasons, the binding
sensorgrams were analysed using the two-state reaction
interaction model. These revealed that VRC01HEK binds FccRIIIa
with rapid on- and off-rates (Figure 1a). The affinity was
620 nM (Figure 3). In contrast, VRC01DXF and VRC01Gal formed
more stable complexes, primarily through slower off-rates,
resulting in approximately one order of magnitude higher
affinity (32.6 and 59 nM, respectively). Additionally, for
VRC01Gal a 28% reduction in saturation level (Rmax) was
observed, indicating that a proportion of molecules are inactive
for FccRIIIa binding. This correlated with 29.4% aglycosylation
in VRC01Gal sample that was detected by LC-ESI-MS (Table 1).
Indeed, when N-glycans were absent, the unglycosylated
antibodies (VRC01aglyco) could not engage the receptor at any
of the tested concentrations (Figure 1c). VRC01WT exhibited an
interesting binding pattern to FccRIIIa, which is characterized by
two aspects. Firstly, the binding responses saturated at 20% of
the expected level, indicating that about 80% of the VRC01WT
molecules cannot engage FccRIIIa at all. Secondly, the remain-
ing 20% of VRC01WT antibodies had a slightly higher affinity
to FccRIIIa than VRC01HEK, estimated to be 430 nM.
Figure 2 Affinity of VRC01 glycovariants to the
human FccRIIa and FccRIIb. SPR sensorgrams
show binding responses at the injection of
different receptor concentrations (0.5–8 lM) over
the Protein A-captured antibodies. Dissociation
constants are calculated from steady-state
responses at a dynamic equilibrium of complex
formation. Maximum response at the saturation
level is marked with dashed horizontal lines.
When the experimentally measured response at
saturation does not overlap with expected
response, theoretical saturation levels are
indicated with solid horizontal lines. Data shown
are from one experiment representative of at least
two technical repeats.
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Affinity to FccRIIa and FccRIIb
Implications of antibody glycovariants were also analysed for two
low-affinity FccRs, FccRIIa and FccRIIb. For this study, the more
prevalent polymorphic variant of FccRIIa (R131) was selected
(Osborne et al., 1994; Warmerdam et al., 1990).
Steady-state affinity measurements revealed that VRC01HEK
binds FccRIIa with an affinity of 937 nM (Figure 2; steady-state
graph data are shown in Figure S3). Binding of the plant-
produced VRC01WT was too low to measure under the assay
conditions, but the affinity of the interaction appears to be lower
than 7 lM. Engineering Fc glycosylation restored binding of plant-
made antibodies to FccRIIa, as demonstrated by VRC01DXF and
VRC01Gal (affinities 780 nM and 1.5 lM, respectively). As with
FccRIIIa, the VRC01Gal preparation appears to contain approxi-
mately 29% inactive molecules, as indicated by a mismatch
between the experimental and theoretical Rmax. This observation
correlates with the extent of aglycosylation measured by mass
spectrometry (Table 1).
Interaction of the VRC01 glycovariants with FccRIIb exhibited a
similar binding pattern as for FccRIIa. Plant-made VRC01WT had
an affinity lower than 7 lM, which was improved in the
glycoengineered variants VRC01DXF and VRC01Gal (2.5 and
3.7 lM, respectively), reaching a similar level to VRC01HEK
(3.4 lM) (Figure 2; steady-state graph data are shown in
Figure S4). VRC01aglyco did not bind FccRIIa and FccRIIb at any
concentration tested, indicating that unglycosylated antibodies
are not able to engage these receptors.
The relative affinities for all antibodies against Fcc receptors,
measured by SPR, are summarized in Figure 3.
Binding to cell-surface FccRs
Binding of VRC01 glycovariants to FccRs was further analysed in a
cellular context, using THP-1 monocytes (Tsuchiya et al., 1980).
Flow cytometric analysis demonstrated that these cells express
FccRI and FccRII receptors on the surface, but no FccRIII could be
observed (Figure 4a). The cells were incubated with VRC01
antibodies, and binding was detected with specific antibody
fragments conjugated to FITC fluorochrome. All antibodies
except VRC01aglyco demonstrated binding to the cells (Figure 4b).
However, VRC01WT did not engage the cell-surface FccRs as
effectively as VRC01HEK. Engineering plant glycosylation
improved binding of the plant-made antibodies to cells
(VRC01DXF and VRC01Gal). The observations are consistent with
the binding results obtained in the SPR-based assays.
To demonstrate a functional impact of increasing binding
affinity to FccRIIIa, an ADCC reporter bioassay was used
(Figure 4c). Dilutions of VRC01WT, VRC01DXF and VRC01HEK
were pre-incubated with HIV-1 gp140, before incubating with
engineered Jurkat effector cells (ADCC Bioassay Effector cells). In
this assay, FccRIIIa activation is directly proportional to the
luciferase activity in the effector cells. FccRIIIa activation induced
by VRC01WT and VRC01HEK was similar. However, FccRIIIa
activation by VRC01DXF was approximately 25-fold higher. This
is consistent with the results of the FccRIIIa analysis described
above as well as other studies (Forthal et al., 2010; Junttila et al.,
2010; Zeitlin et al., 2011). Luciferase activity of control samples
with no antibody (gp140 + cells only) or no gp140 (mAb + cells
only) was not significantly different to PBS (data not shown).
Binding to FcRn
FcRn is an important receptor that can influence and modulate
the course of antibody-based therapy. Although the exact
binding mechanism in vivo is still unclear, recent studies provide
strong evidence that each IgG heavy chain can bind one FcRn
molecule independently with identical affinity (Abdiche et al.,
2015; Oganesyan et al., 2014). The resulting 2 : 1 FcRn–IgG
complex is then characterized by stronger interaction due to
avidity (Tesar et al., 2006).
SPR analysis was performed in two assay orientations. FcRn was
either immobilized on the sensor chip surface allowing antibodies
to slot between two receptors, resulting in strong avidity
interaction, or they were injected in solution over an antibody-
coated surface allowing for independent interaction with each
antibody arm. Due to the pH-dependent nature of the interac-
tion, where antibodies engage the receptor in acidic conditions of
the endosome and are released at physiological pH of the blood
(Vaughn and Bjorkman, 1998), the binding in this assay was
Figure 3 Affinity of VRC01 glycovariants to
human FccRs. The graph summarizes the affinity
values (KD) for the interaction of different
glycovariants with human FccRI, FccRIIa, FccRIIb
and FccRIIIa.
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measured at pH 6.0. In the first strategy, different VRC01
glycovariants were injected at 200 nM in duplicate (Figure 5a).
The sensorgrams show that VRC01HEK generates the highest
binding responses, indicating higher affinity, followed by all plant-
produced variants, which have comparable binding levels,
including unglycosylated VRC01. Formation of stable multivalent
complexes was observed, as characterized by very slow dissoci-
ation curves. All the complexes dissociated efficiently at physio-
logical pH 7.4. In the second, avidity-free assay orientation,
soluble monomeric FcRn was injected at 200 nM in duplicate
(Figure 5b). Again, VRC01HEK generated the highest binding
responses and FcRn bound all the plant-produced variants
similarly, to a level of around 2/3 of VRC01HEK. The observed
difference suggests a higher affinity of VRC01HEK to FcRn;
however, the presence of partially degraded antibodies in plant
samples is commonly found (Hehle et al., 2011) and could also
cause a decrease in observed binding levels. Therefore, affinity
values for all VRC01 glycovariants to recombinant human FcRn
was measured in a steady-state affinity assay. Briefly, each
antibody was captured to the same level onto an anti-human Fab
surface, followed by injection of FcRn at a range of concentra-
tions (Figure S5). The steady-state affinity measurements revealed
that all glycoforms have a fairly similar affinity to FcRn, with
VRC01HEK exhibiting slightly higher affinity (199 nM) than the
plant-produced variants (272–310 nM). The difference is unlikely
to result from different plant glycosylation, given that neither
glycoengineering (VRC01DXF and VRC01Gal) nor removing the Fc
glycan (VRC01aglyco) affected antibody affinity to the receptor
significantly. Another possibility might be antibody oxidation,
which has been previously reported to reduce antibody affinity to
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Figure 4 Binding of monomeric VRC01
glycovariants to cell-surface Fc receptors on THP-1
monocytes. (a) Flow cytometric analysis with FITC-
conjugated antibodies specific to FccRI, FccRII or
FccRIII on the surface of THP-1 cells (red
histograms) as compared to the isotype controls
(blue histograms). The numbers indicate mean
fluorescent intensity (MFI) of the populations. (b)
Binding of serially diluted VRC01 antibodies to
THP-1 cells was detected with a FITC-labelled F
(ab’)2 fragment against human antibodies using
flow cytometry. MFI responses were corrected by
subtracting background response levels from cells
incubated with the FITC-labelled F(ab’)2 fragment
only (no VRC01). Nonlinear regression curve fit
was applied. The results represent one of two
biological repeats. (c) FccRIIIa activation by
VRC01WT, VRC01DXF and VRC01HEK was
demonstrated by luciferase activity of ADCC
Bioassay Reporter cells. Antibodies were pre-
incubated with HIV-1 UG37 gp140 before
effector cells (Jurkat NFAT-luc) were added.
Luciferase activity was the average result of three
independent experimental repeats. Error bars
equals  SD and PBS was used as negative
control. * VRC01DXF at 10 lg/mL was omitted
because the readings exceeded the range of the
assay.
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FcRn (Bertolotti-Ciarlet et al., 2009; Pan et al., 2009), and this
was investigated in the next experiment.
Methionine oxidation
It was previously observed that oxidation of two methionine
residues, Met252 and Met428, on the antibody heavy chain can
result in up to 10-fold reduced affinity to FcRn (Bertolotti-Ciarlet
et al., 2009; Gao et al., 2015). The plant-made VRC01 samples,
together with a new VRC01HEK batch, were therefore analysed to
measure percentage oxidation of these two methionine residues.
Heavy chains were separated by gel electrophoresis and enzy-
matically digested to corresponding peptides containing Met252 or
Met428 residues: DTLM252ISR and SCSVM428HEALHNHY. The
relative percentage oxidation was calculated from MS spectra, by
comparing a proportion of the peak heights corresponding to an
oxidized versus nonoxidized peptide containing either the Met252
or Met428 residues. The sequence identity of oxidized and
nonoxidized peptides (both DTLM252ISR and SCSVM428HEALHNHY),
as well as formation of methionine sulfoxide (MetOx), was further
confirmed by MS-MS (data not shown).
Figure 5 Binding analysis of VRC01 glycovariants to FcRn. (a) Human recombinant FcRn ectodomains were covalently immobilized on the CM5 sensor chip
surface and different VRC01 glycovariants were injected at 200 nM concentration in duplicate. Data shown are from one experiment representative of at
least two technical repeats. Binding and dissociation of different antibodies was observed at pH 6.0, and the FcRn surface was regenerated with PBS (pH
7.4). (b) Each VRC01 glycovariant was captured onto the anti-human Fab surface to the same level and tested for binding to 200 nM FcRn. Sensorgrams
represent binding and dissociation at pH 6.0 for two independent repeats. Maximum binding level is marked with a dashed horizontal line.
Figure 6 Methionine oxidation of VRC01 glycovariants. (a) Percentage oxidation of Met252 and Met428 on antibody heavy chains, as determined by mass
spectrometry. All plant-made VRC01 glycovariants were produced at the same time under the same conditions and stored in nonoxidizing atmosphere.
Data shown are from one experiment representative of at three biological repeats. (b) Relative affinity of plant-made VRC01 glycovariants to FcRn
compared to VRC01HEK. Values obtained from SPR analysis.
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Mass spectrometry analysis of methionine oxidation revealed
that all the plant-produced VRC01 antibodies contained signifi-
cantly more methionine sulfoxide in the Met252 position (50%–
70%) as compared to VRC01HEK (20%) (Figure 6). Met428
displayed a different oxidation pattern than Met252, with
VRC01HEK and all plant antibody glycovariants having similar
oxidation levels 50%–76%.
Four separate batches of VRC01WT were subsequently pro-
duced to investigate the possibility of controlling Met252 and
Met428 oxidation during plant antibody extraction, purification
and storage. The batches of VRC01WT were prepared, with and
without the addition of an antioxidant during antibody extrac-
tion, and stored under nitrogen gas or not. Mass spectrometry
analysis of methionine oxidation was performed as above. There
was no significant difference in Met252 or Met428 oxidation
between any of the downstream processing strategies (data not
shown), suggesting that methionine oxidation is likely to take
place in planta, rather than during antibody extraction and
storage.
Discussion
Four activating receptors, FccRI, FccRIIa, FccRIIc and FccRIIIa,
and one inhibitory receptor, FccRIIb (Ravetch, 2010), are
differentially distributed on immune cells. They can be found
on all leucocytes and platelets except T cells (Guilliams et al.,
2014; Hogarth and Pietersz, 2012), and many cells have
multiple FccRs on their surface. Once bound to antigen,
antibodies can mediate a range of immune functions through
interaction with FccR. Engagement of activating FccRs can
induce (i) antibody-dependent cell-mediated cytotoxicity (ADCC)
or antibody-dependent cell-mediated phagocytosis (ADCP),
which both result in direct killing of antibody-opsonized cells,
(ii) release of pro-inflammatory mediators and cytokines, to
attract other white blood cells to the infection site and activate
them, and (iii) antigen endocytosis and presentation, to further
enhance the immune response (reviewed in Desjarlais and
Lazar, 2011).
In order to study the effect of plant N-glycosylation on
recombinant antibody Fc-mediated binding activities, the broadly
neutralizing HIV antibody, VRC01, was expressed in plants in
different glycol formats. Our studies revealed that VRC01 with
typical plant glycosylation had 30-fold lower affinity to recombi-
nant human FccRI than the same antibody produced in HEK cells.
Also, it had a limited ability to bind the low-affinity receptors
FccRIIa, FccRIIb and FccRIIIa. Removal of Fc glycans by mutage-
nesis of Asn297 resulted in a complete loss of binding. However,
engineering plant glycans by removal of core fucose and xylose
significantly improved affinity of plant-made VRC01 to FccRI and
restored binding activity to FccRIIa and FccRIIb. Moreover, affinity
of fucose/xylose-free antibodies to FccRIIIa was 10–20 times
enhanced as compared to the HEK cell-derived VRC01. The
impact of fucose removal on binding to FccRIIIa was previously
observed for antibodies generated in mammalian cell and plant-
based systems (Cox et al., 2006; Shields et al., 2002) and likely
results from steric interference with glycans present in the binding
site of FccRIIIa (Ferrara et al., 2011). Extending the fucose- and
xylose-free antibodies with terminal b1,4-galactose residues did
not further improve their interaction with Fc-gamma receptors.
Cell-based binding assays with THP-1 monocytes confirmed the
binding behaviour of different VRC01 glycovariants observed in
the SPR analysis.
The binding of VRC01WT to FccRIIIa indicated that about 80%
of antibody molecules did not engage the receptor. The remain-
ing active proportion had an affinity of 430 nM, as compared to
620 nM for VRC01HEK. The inactive proportion correlates with the
proportion of molecules either with no Fc glycans or containing
typical plant GnGnXF3 structures. This suggests that not only
unglycosylated antibodies, but also GnGnXF3 glycoforms might
not be able to bind FccRIIIa. The core fucose in plants is a1,3-
linked, rather than the a1,6-link in mammalian systems, but the
results suggest the differentially oriented fucose on plant-
produced antibodies still causes steric constraints in the FccRIIIa
binding site, abrogating the interaction. The active portion of
VRC01WT antibodies, which engages FccRIIIa more effectively
than VRC01HEK, might correspond to the non-fully processed
glycoforms that were found in the sample. These comprise
oligomannose structures lacking core fucose and truncated
complex glycans containing fucose. Thus, VRC01WT antibody
produced in plants appears to be a mixture of FccRIIIa nonbinders
and binders with different affinities, depending on the glycoform
they carry. This variability may translate functionally into poten-
tially different ADCC activities.
Nonglycosylation had a significant effect on antibody–receptor
binding. Glycopeptide analysis revealed that all VRC01 antibody
preparations contained a proportion of unglycosylated heavy
chains. This was very low in the HEK-derived VRC01 (<5%), but
reached higher levels when the antibody was expressed in
N. benthamiana (21%–35% depending on the glycoengineering
strategy). Recombinant glycoproteins generated in plant systems
are often fully glycosylated; however, some studies have previ-
ously reported partial aglycosylation of plant-made antibodies
(Jez et al., 2012; Schuster et al., 2007; Teh et al., 2014; Zeitlin
et al., 2011). The reason for hypoglycosylation of some plant-
made antibodies is unknown, but seems to be antibody specific.
A powerful strategy for enhancing glycosylation efficiency is the
over-/co-expression of the oligosaccharyltransferase complex
(OST), which is the central-protein complex facilitating the N-
glycosylation of proteins in the lumen of the endoplasmic
reticulum (Castilho et al., 2018).
Serum antibodies naturally demonstrate a high level of glycan
heterogeneity, exhibiting as many as 30–40 different glycoforms
(Nimmerjahn and Ravetch, 2008; Stadlmann et al., 2008). The
functional relevance of such glycan heterogeneity is not fully
understood; however, the glycoform profile may be skewed in
pathology or in response to pathogens (Ackerman et al., 2013;
Jefferis, 2012). This indicates that glycan heterogeneity might be
important and antibodies with heterogeneous glycoprofile might
actually be preferred over those with a single glycoform.
However, a better understanding of the role of individual glycan
residues is needed first, before we can start to consider how best
to mimic a natural antibody response.
At present, therapeutic monoclonal antibodies are generally
obtained from mammalian cell-based production systems which
usually generate a mixture of about 5–9 different glycoforms
(Stadlmann et al., 2008). Given that individual glycoforms may
have different functional activities, such a mixture may potentially
contain antibody molecules with limited or no activity. In future,
control of the glycosylation profile of monoclonal antibodies for
therapeutic use may therefore need to be considered more
carefully. An ultimate goal might be to develop a reproducible
optimized mix of glycoforms for a specific application.
Attempts to isolate a single glycoform from a heterogeneous
mixture of glycovariants by affinity chromatography have met
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with limited success (Bolton et al., 2013), and purification of a
single glycoform is currently not feasible (Loos and Steinkellner,
2012). Several approaches have been undertaken to reduce
antibody glycosylation heterogeneity, including use of glycan-
modifying enzymes in vitro (Thomann et al., 2015) and genetic
modification (Piron et al., 2015). Plants offer an attractive
solution for producing highly homogeneous antibodies and other
proteins with defined glycosylation (Madeira et al., 2016; Mon-
tero-Morales and Steinkellner, 2018). Although expression of
antibodies in WT plants can yield a proportion of non-fully
processed glycans, glycoengineered plant lines usually produce
highly homogeneous glycoforms (Ma et al., 2015a; Strasser
et al., 2008, 2009). Here, VRC01 antibody generated in DXF
N. benthamiana contained a single predominant glycoform,
GnGn, accompanied by MGn (4.7%). Although LC-ESI-MS
analysis suggested the presence of 20% of unglycosylated heavy
chains, this could not be confirmed in Western blot or SPR
analyses. Typically, inactivation of endogenous glycosyltrans-
ferases in plants results in over 80% purity of GnGn glycoforms
(Castilho et al., 2015; Strasser et al., 2008). Galactosylated
VRC01Gal produced in this study by transient co-expression of
human galactosyltransferase was characterized by high hetero-
geneity; however, a recently developed plant transgenic platform
is able to produce antibodies lacking core fucose and xylose
where 90% of molecules carry galactosylated N-glycans, includ-
ing 60% of bi-galactosylated structures (AA) (Schneider et al.,
2015).
Antibody binding to neonatal Fc receptor is reported to be
independent of Fc glycosylation (Nezlin and Ghetie, 2004), as
FcRn engages residues present on the CH2–CH3 domain interface
(Burmeister et al., 1994; Oganesyan et al., 2014), but a concern
was raised that unusual glycan structures from nonmammalian
protein expression systems may affect the binding indirectly
(Jefferis, 2009a). Our SPR analysis confirmed that plant N-
glycosylation did not have an adverse effect on binding to FcRn.
All plant VRC01 glycovariants had similar affinity to FcRn that was
slightly lower than VRC01 from HEK cells. However, binding
reduction correlated with increased oxidation levels of a methion-
ine residue (Met252) present in the Fc region, which has
previously been reported to have a negative impact on the IgG–
FcRn interaction (Gao et al., 2015).
Protein oxidation in recombinant protein production is an
important factor influencing stability and functionality of protein
pharmaceuticals (Li et al., 1995; Pan et al., 2009). Susceptible
amino acids, like His, Met, Cys, Tyr and Trp, can be oxidized by a
number of factors at any stage of the production, extraction,
purification and storage (Manning et al., 2010). Methionine
residues are particularly sensitive to reactive oxygen species and
can oxidize to methionine sulfoxide even in the presence of
molecular oxygen. Different methionine residues can oxidize at
different speeds, with surface-exposed residues oxidizing faster,
whereas those buried in a protein backbone oxidize more slowly
(Griffiths and Cooney, 2002).
Extraction of recombinant proteins from plant tissues presents
many challenges. Plant leaves are rich in polyphenols (Li et al.,
2003), which, in response to tissue damage and exposure to air,
are enzymatically oxidized to reactive semiquinone radicals and
quinones, which further attack sensitive residues on proteins
(Met, Cys, Trp) (Synge, 1975). Polyphenol oxidation can also
occur during protein extraction from plants (Hurrell et al., 1982).
It has also been reported that during extraction, methionine
sulfoxide is formed (Pirie, 1975). Protection of recombinant
proteins from oxidation during plant extraction has not been
widely studied; however, general preventive procedures have
been used, for example thiosulfate, citrate (Chargelegue et al.,
2005), ascorbic acid or Gamborg’s B5 vitamin solution (Miletic
et al., 2015). Reducing polyphenol oxidation can be attempted by
addition of chelating agents like EDTA, and sometimes sucrose is
also included, to limit solvent accessibility (Miletic et al., 2015). In
our study, oxidation of Met252 and Met 458 was unaffected by
antioxidant in the antibody extraction buffer, or storage in
nonoxidizing conditions after extraction. Although further studies
are required, this suggests that antibody oxidation may occur at
an earlier stage in antibody expression, pointing to the likelihood
that antibody mutagenesis strategies (Dall’Acqua et al., 2002;
Zalevsky et al., 2010) might prove more useful.
In conclusion, this is a comprehensive report of the impact of
two post-translational modifications affecting antibodies pro-
duced in plants, on their Fc effector functions. We demonstrated
the importance of glycosylation for binding to high- and low-
affinity Fcc receptors and the potential role of glycoengineering
strategies in plants to produce antibodies with potent opsoniza-
tion and ADCC activity. We extended our studies to formally
demonstrate that plant glycosylation does not significantly affect
binding of antibodies to FcRn receptor, but that oxidation of at
least one methionine residue in the Fc region has an impact on
FcRn affinity. Our results suggest that the reported accelerated
clearance of some plant-produced antibodies from the blood-
stream (Ko et al., 2003; Rosenberg et al., 2015; Triguero et al.,
2011) might be attributable to this and other clearing
mechanisms.
Materials and methods
VRC01HEK was obtained from the Centre for AIDS
Reagents, UK
Site-directed mutagenesis and gene cloning
VRC01 heavy- and light-chain gene sequences were plant-codon-
optimized for tobacco (provided by Mapp Biopharmaceutical,
Inc.). The heavy-chain sequences were mutagenized using the
QuikChange (Stratagene) protocol and primers designed to
replace the Asn codon with Ser at position 297. Transformed
colonies were selected and plasmids were isolated using
QIAprep Spin Miniprep Kit (Qiagen) and confirmed by sequenc-
ing. Both mutated and original sequences of VRC01 light and
heavy chains were subcloned into the plant expression vector
pEAQ-HT-DEST3 (Sainsbury et al., 2009) by LR recombination
using the Gateway cloning system (Invitrogen). DH5a competent
E. coli cells were transformed, and colonies containing pEAQ-HT
vectors with appropriate gene constructs were selected using
kanamycin. Expression vectors were isolated by QIAprep Spin
Miniprep Kit (Qiagen).
Antibody expression in N. benthamiana and purification
Expression vectors pEAQ-HT-DEST3 containing heavy and light
genes were introduced into two different Agrobacterium tume-
faciens strains: GV3101:pMP90 was used for the heavy-chain
construct and LBA4404 for the light-chain construct. Agrobacte-
ria were grown overnight at 28 °C in YENB medium with 50 lg/
mL rifampicin and appropriate antibiotics to select for helper
plasmid and expression vector. For infiltration, bacteria were
resuspended in 0.1 mM acetosyringone (Santa Cruz Biotechnol-
ogy), 0.01 mM MES (Sigma, Poole, UK) and 0.01 mM MgCl2
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(VWR International, UK) to a final OD600 of 0.2. Vacuum
infiltration of N. benthamiana leaves was performed as previously
described (Kapila et al., 1997), using 4-week-old plants and
applying vacuum for 1 min at 100 mbar. To produce glycoengi-
neered VRC01 antibodies (VRC01DXF), the N. benthamiana DXF
plant line (Strasser et al., 2008) was used for agroinfiltration. To
generate the galactosylated glycovariant (VRC01Gal), the DXF
N. benthamiana plants were additionally co-infiltrated with
agrobacteria containing pST plasmid with human b1,4-galacto-
syltransferase (GalT) (Strasser et al., 2009). Vacuum infiltrated
leaves were harvested at 6 days postinfection. Antibodies were
extracted in 100 mM Tris buffer (pH 8.0) and 150 mM NaCl and
purified using a Protein A-Agarose (Sigma) column, eluting
antibodies with 0.1 M glycine–HCl (pH 2.7) into 1 M Tris–HCl
(pH 9.0) neutralizing buffer. Purified samples were dialysed into
PBS with Slide-A-Lyzer Cassettes (molecular cut-off 3.5 kDa;
Thermo Scientific, Waltham, MA, USA) and stored under nitrogen
in glass HPLC tubes with septum (10 mm PP Screw Cap; Fisher
Scientific, Loughborough, UK).
For cell assays, the concentration of full-size antibodies was
calculated using densitometry analysis of identified IgG band on
Coomassie-stained SDS-PAGE gels. Standard curves for known
concentrations of bovine serum albumin and another plant-
derived IgG antibody (P2G12) were generated using the BCA
Protein assay, and VRC01 concentration values were interpolated
from nonlinear regression fit using second-order polynomial
(quadratic) equation.
In the experiment to control antibody oxidation during
processing and storage, VRC01WT was expressed in the same
way except that antibodies were extracted using PBS (pH 7.4)
with or without 10 mM sodium metabisulfite.
LC-ESI-MS confirmation of glycoengineering
Following separation by SDS-PAGE under reducing conditions,
heavy-chain bands were excised, S-alkylated with iodoacetamide
and digested with sequencing-grade modified trypsin (Promega,
Southampton, UK). Fragments were eluted from the gel with
50% (vol/vol) acetonitrile and loaded on a BioBasic C18 column
(BioBasic-18, 150 9 0.32 mm, 5 lm; Thermo Scientific) using
65 mM ammonium formate buffer as the aqueous solvent. A
gradient from 5% B (B: 100% acetonitrile) to 32% B in 45 min
was applied at a flow rate of 6 lL/min, followed by a 15-min
gradient from 32% B to 75% B that facilitates elution of large
peptides. Detection was performed with a QTOF MS (Bruker
maXis 4G) equipped with the standard ESI source in positive-ion,
data-dependent mode (=switching to MSMS mode for eluting
peaks). MS scans were recorded (range: 300–2000 Da), and the 6
highest peaks were selected for fragmentation. Instrument
calibration was performed using an ESI calibration mixture
(Agilent, Santa Clara, CA, USA). Results were evaluated using
Data Analysis 4.0 (Bruker). Co-eluting glycopeptide peaks were
identified by their exact mass.
FccR binding kinetics and affinity measurements
SPR assays were performed using a BiacoreTM X100 instrument
(GE Healthcare, Little Chalfont, UK). First, a protein A sensor chip
was prepared by immobilizing recombinant protein A (Sigma) in
both flow cells of a CM5 sensor chip to 5000 RU using the Amine
Coupling Kit (GE Healthcare). VRC01 samples were diluted in
HBS-EP+ buffer and captured onto the Protein A surface (flow cell
2) to the levels around 240RU (for FccRI analysis) or 330RU (for
FccRIIIa) or 680RU (for FccRIIa and FccRIIb). Recombinant human
FccR ectodomains (R&D) were injected over both flow cells at
25 °C for 135 s at 40 lL/min (FccRI), 40 s at 50 lL/min (FccRIIIa
when tested against fucosylated antibodies), 90 s at 40 lL/min
(FccRIIIa when tested against afucosylated antibodies) or 30 s at
45 lL/min (FccRIIa and b). The FccR–VRC01 complexes were
removed with two 90-s injections of 10 mM glycine–HCl (pH 1.5).
If the regeneration was not fully successful, the first injection was
replaced with 10 mM glycine–HCl–3.5M MgCl2 (pH 1.5) buffer.
Receptors were analysed at the following concentrations: FccRI—
2–240 nM (480 nM for VRC01aglyco); FccRIIIa—0.125–4 lM (12–
800 nM for afucosylated antibodies VRC01DXF and VRC01Gal);
and FccRIIa and FccRIIb—0.5–8 lM. Half-life of antibody–receptor
complexes was calculated from dissociation rate constants
according to the formula: T1/2 = ln2/koff.
Surface expression of FccRs on THP-1 cells
The THP-1 cell line (ATCC) was grown in RPMI culture medium at
37 °C and 5% CO2 atmosphere. The cells were harvested by
centrifugation (300 RCF, 5 min) and concentrated to
2 9 106 cells/mL in PBS with 2.5% BSA and 0.1% sodium azide
(FACS buffer). To determine FccRI expression, the cells were
incubated with 10 lg/mL mouse anti-human FccRI antiserum
(R&D) for 1 h on ice. Mouse IgG1 (Sigma) was used as an isotype
control. The cells were washed twice with the FACS buffer by
centrifugation at 300 RCF for 5 min and incubated with 1 : 100
FITC-conjugated anti-mouse immunoglobulins antibody (The
Binding Site). For FccRII and FccRIII expression, the cells were
incubated with 0.25 lg/test of FccRII-FITC or FccRIII-FITC anti-
body (eBioscience) for 1 h on ice. Mouse IgG1-FITC (BD
Biosciences) was used as an isotype control. The cells were
washed twice, and fluorescence intensity was measured by BD
FACSCantoTM II Flow Cytometer (BD Biosciences) using BD
FACSDivaTM software. The data were analysed using FlowJo
V10.1 software.
VRC01 binding to cell receptors
THP-1 cells were harvested by centrifugation (300 RCF, 5 min)
and concentrated to 5 9 106 cells/mL in FACS buffer. The cells
were incubated with serially diluted VRC01 samples for 1 h on
ice, and excess antibodies were washed off twice with FACS
buffer by centrifugation at 300 RCF for 5 min. Binding of VRC01
samples to THP-1 cells was detected with 1 : 200 FITC-conju-
gated F(ab’)2 fragment against human Ig light and heavy chains
(Jackson ImmunoResearch Laboratories, Inc.) by 20-min incuba-
tion on ice. The cells were washed twice, and fluorescent intensity
was measured by BD FACSCantoTM II Flow Cytometer (BD
Biosciences). Mean fluorescent intensity (MFI) values were derived
by subtracting MFI of THP-1 cell populations treated with the F
(ab’)2 fragment only. Binding curves were created using nonlinear
curve fit (One site – Specific binding) with GraphPad Prism 6
software.
FccRIIIa activation reporter assay
The ADCC Reporter Bioassay was performed according to the
manufacturer’s protocol (Promega), using soluble HIV-1 UG37
gp140 (CFAR, UK) instead of target cells. 0.08, 0.4, 2 and 10 lg/
mL antibody was pre-incubated with free HIV-1 gp140 (5 lg/mL)
for 1 h. ADCC Bioassay Effector cells (Jurkat cells stably express-
ing the high-affinity (V158) FccRIIIa receptor and an NFAT
response element driving expression of firefly luciferase) were
added at 1.5 9 105 cells/well, and the assay plates were
incubated at 37 °C and 5% CO2 for 24 h. Bio-Glo
TM luciferase
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assay reagent was added and luminescence measured in a
GloMax 96 plate reader (Promega). In this assay, luciferase activity
in the effector cells is directly proportional to FccRIIIa activation.
FcRn binding analysis
For binding analysis, two strategies were employed. Firstly,
recombinant human FcRn ectodomain (SinoBiological Inc., Bei-
jing, China) was diluted in 10 mM acetate buffer (pH 4.5) and
immobilized on the CM5 sensor chip surface to 1000 RU by
amine coupling (Amine Coupling Kit; GE Healthcare). Reference
surface was ‘blank-immobilized’ by activation with NHS/EDC and
blocking with 1 M ethanolamine–HCl (pH 8.5). Binding analysis
was performed in PBS-P+ buffer (PBS 0.05% Tween-20) (pH 6.0).
To minimize differences in pH between different samples, VRC01
antibodies were prediluted to 1200 nM in PBS (pH 7.4) and then
injected at 100 nM in PBS-P+ (pH 6.0) for 120 s contact time and
120 s dissociation time at a flow rate of 40 lL/min. Samples were
run in duplicate, and the surface was regenerated with a 60-s
injection of PBS (pH 7.4).
In the second strategy, anti-human Fab antibodies (Fab
Capture Kit) were diluted to 20 lg/mL in 10 mM acetate buffer
(pH 5.0) and immobilized on a CM5 sensor chip to 6000 RU in
both flow cells, by amine coupling. VRC01 antibodies were then
captured in flow cell two only. Recombinant human FcRn
(SinoBiological) was injected over the antibody surface at
100 nM for 60 s at a flow rate of 30 lL/min with 90 s dissociation
time. All samples were run in PBS-P+ (pH 6.0) running buffer and
were analysed in duplicate. The chip surface was regenerated
with 10 mM glycine–HCl (pH 2.1).
For FcRn affinity measurements, VRC01 antibodies were
captured on the anti-Fab surface. Recombinant human FcRn
ectodomains (SinoBiological) were injected over the antibody
surface at a range of concentrations (12.5–800 nM in PBS-P+, pH
6.0) for 40 s at a flow rate of 30 lL/min and with 60 s
dissociation time. After each injection, the antibody surface was
regenerated with PBS (pH 7.4). 10 mM glycine–HCl (pH 2.1) was
used to remove antibodies from the anti-Fab surface. Binding
responses at 10 s after injection from the double-referenced
sensorgrams were selected for affinity evaluation using a steady-
state affinity model (BiacoreTM X100 Evaluation Software).
Methionine oxidation
The heavy and light chains of purified antibody samples were
separated by 12% Bis-Tris NuPAGE polyacrylamide gel elec-
trophoresis. Heavy chains were excised from the gel and washed
three times for 15 min at RT with 0.1 M NH4HCO3 (pH 8) and
100% CH3CN (v:v). The samples were dried in a SpeedVac
centrifuge (Thermo Fisher, Waltham, MA, USA). After reduction
with 0.1 M dithiothreitol (DTT) for 45 min at 56 °C and alkylation
with 55 mM iodoacetamide (IAA) performed in 0.1 M NH4HCO3
(pH 8) for 30 min at room temperature in the dark, 3 lg of
proteomic-grade trypsin was added (Promega) per sample and
placed at 4 °C for 30 min prior to overnight incubation at 37 °C.
The trypsin was inactivated by heating for 5 min at 100 °C. The
samples were cooled to RT and digested with 5 lg of chy-
motrypsin (Sigma) for 4 h at 37 °C. The chymotrypsin was
inactivated by heating 5 min at 100 °C. After the protease
digestions, the gel pieces were incubated in solutions of 50%
CH3CN, 5% formic acid, 0.1 M NH4HCO3 and 100% CH3CN and
finally in 5% formic acid to extract the resulting peptide and
glycopeptide mixture. The sample was dried before further
analysis by QTOF Agilent Technologies LC-Chip MS for high-
sensitivity nanospray LC-MS (Agilent Technologies) as previously
reported (Vanier et al., 2015).
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